返回 
加入收藏
匹多莫德治疗支气管哮喘合并反复呼吸道感染患儿的临床研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 匹多莫德治疗支气管哮喘合并反复呼吸道感染患儿的临床研究 |
| TITLE： | |
| 摘要： | 目的：探讨匹多莫德治疗哮喘合并反复呼吸道感染患儿的临床效果，以及对患儿免疫球蛋白和相关指标的影响。方法：将我院2011年3月－2013年5月收治的120例哮喘合并反复呼吸道感染患儿，按随机数字表法分为试验组和对照组，各60例。对照组患儿采取常规糖皮质激素疗法，试验组患儿在对照组基础上加用匹多莫德口服溶液0.4 g，po，bid，共治疗14 d。观察两组患儿治疗前后的临床指标（呼吸道感染次数、发热天数、咳嗽天数、喘息发作天数和抗菌药物使用天数）、血清指标[β-防御素1（hBD-1）、免疫球蛋白A（IgA）、IgG、IgM、尿素（UREA）、丙氨酸转氨酶（ALT）]和咽拭子检测结果，以及不良反应发生情况。结果： 治疗前，两组患儿的临床指标、血清指标和咽拭子检测结果比较，差异均无统计学意义（P＞0.05）。治疗后，试验组患儿的临床指标均较治疗前及对照组显著减少或缩短，血清hBD-1、IgA、IgG水平均较治疗前及对照组显著升高，差异均有统计学意义（P＜0.05）；对照组患儿的临床指标和血清指标，以及试验组患儿血清IgM、UREA和ALT水平与治疗前比较，差异均无统计学意义（P＞0.05）。两组患儿呼吸道感染病原菌种类和数量均较治疗前显著减少，且试验组显著少于对照组，差异均有统计学意义（P＜0.05）。两组患儿均未见明显不良反应发生。结论：匹多莫德治疗哮喘合并反复呼吸道感染患儿具有较好的临床效果，可提高患儿的免疫力，减少病原菌种类和数量，且安全性较高。 |
| ABSTRACT： | OBJECTIVE： To investigate the clinical effects of pidotimod in the bronchial asthma complicated with recurrent respiratory tract infection， and its effects on immunoglobulin and related indexes. METHODS： A total of 120 bronchial asthma patients with recurrent respiratory tract infection selected from our hospital during Mar. 2011-May 2013 were divided into trial group and control group according to random number table， with 60 cases in each group. Control group received routine corticosteroid therapy， and trial group was additionally given Pidotimod oral solution 0.4 g， po， bid， for 14 d， on the basis of control group. Clinical indexes （the times of respiratory infection， the duration of fever， cough， wheezing attack and antibiotics use）， serum indexes [β-defensin-1 （hBD-1）， immunoglobulin A （IgA）， IgG， IgM， UREA， ALT]， the results of pharynx test before and after treatment， and the occurrence of ADR were observed in 2 groups. RESULTS： Before treatment， there was no statistical significance in clinical indexes， serum indexes， the results of pharynx test between 2 groups （P＞0.05）. After treatment， clinical indexes of trial group were significantly lower or shorter then before treatment or control group， while serum levels of hBD-1， IgA and IgG were significantly higher than before treatment or control group， with statistical significance （P＜0.05）. There was no statistical significance in clinical indexes and serum indexes of control group， serum levels of IgM， UREA and ALT in trial group before and after treatment （P＞0.05）. The types and number of pathogenic bacteria of respiratory tract infection were decreased significantly in 2 groups， and the trial group was significantly less then the control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Pidotimod shows good clinical effects on bronchial asthma complicated with recurrent respiratory tract infection， can improve immunity and reduce the types and number of pathogenic bacteria with good safety. |
| 期刊： | 2017年第28卷第20期 |
| 作者： | 周雪梅，陆立东，黄建萍 |
| AUTHORS： | ZHOU Xuemei，LU Lidong，HUANG Jianping |
| 关键字： | 匹多莫德；支气管哮喘；反复呼吸道感染；β-防御素1；免疫球蛋白 |
| KEYWORDS： | Pidotimod； Bronchial asthma； Recurrent respiratory tract infection； β-defensin-1； Immunoglobulin |
| 阅读数： | 307 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
